Orexo: Deprexis reimbursed under the US Veterans Affairs Federal Supply Schedule - Redeye

Redeye maintains its positive view and reiterates our Base Case of SEK 42 per share. The announced Veterans Affairs Federal Supply Schedule contract for deprexis® in the US, an evidence-based digital therapy for the treatment of symptoms of depression, is an important milestone in Orexo’s advancements in the commercialization of the company’s digital therapies.

Länk till analysen i sin helhet: https://www.redeye.se/research/848493/orexo-deprexis-reimbursed-under-the-us-veterans-affairs-federal-supply-schedule?utm_source=finwire&utm_medium=RSS